The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.
A curation working group established a framework that considers the nature and strength of the available evidence when evaluating gene-disease associations.
The company, which has offices in Italy and New York, outsources the analysis to partner laboratories and offers genetic counseling as an option.
Based on evidence the company submitted on the test, and helped by its low pricing, Color also has preferred provider status with a number of plans.
The company, which has been offering its hereditary cancer risk test at a self-pay rate of around $250, will continue to work with insurers to grow in-network status.
The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring.
The researchers found preliminary evidence that some inherited cancer mutations may be more or less common in African-American women than Caucasian women.
Out of 450 patients with early-onset colorectal cancer, 16 percent carried a known risk mutation for hereditary cancer, including for cancers other than colorectal.
Invitae will test 1,000 breast cancer patients from TME practices using its hereditary cancer test, regardless of whether they meet current eligibility criteria.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.